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tatin treatment results in a reduction of cardiovascular (CV)
events during the ﬁrst year of treatment. This study was con-
ducted to estimate the early clinical and economic consequences
of initiating statin therapy with atorvastatin vs. simvastatin
from a Canadian societal perspective. METHODS: A cost-
consequence model was developed to estimate CV events and
costs over the ﬁrst 2 years of treatment associated with initiating
atorvastatin or simvastatin in a hypothetical cohort of 100,000
patients. Four groups of new users were considered, including
patients with: 1) diabetes; 2) multiple CV risk factors; 3) coro-
nary heart disease; and 4) acute coronary syndrome. RCT data
were used to estimate the CV event rate for each statin. CV
events included myocardial infarction, stroke, and revasculariza-
tion procedures. Corresponding direct costs (i.e., health care
utilisation, drug) were obtained from the Ontario Drug Beneﬁt
and Ontario Case Costing Initiative. Estimates of indirect costs
(loss of productivity) were obtained from Statistics Canada. All
costs were expressed in 2007 Canadian dollars. Multivariate
(Monte Carlo simulation) and univariate sensitivity analyses
were conducted on model assumptions. RESULTS: Within two
years of treatment initiation, the use of atorvastatin is predicted
to prevent 1648 CV events (95% CI: 1343–1956) per 100,000
new patients compared with simvastatin. Similarly, the cost of
CV events was reduced by $50.8 million (95% CI: $41.9–$59.8).
The incremental cost associated with atorvastatin treatment
was $31.3 million. This resulted in a net saving of $19.5 million
(95% CI: $10.7–$28.7). Savings were also observed across all
four groups considered. Results were sensitive to assumptions
regarding simvastatin efﬁcacy and levels of persistence. CON-
CLUSION: Based on this model, atorvastatin use is predicted to
result in cost savings to the Canadian society over simvastatin use
within 2 years of therapy initiation.
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OBJECTIVE: Clinical guidelines recommend frequent follow-up
visits for patients initiating antidepressant treatment in order to
provide patient support, adjust dosage, and monitor side effects
and clinical response. We examined the frequency of follow-up
visits and factors associated with having guideline concordant
care during the acute phase of antidepressant treatment.
METHODS: Medical and prescription claims from a large
national health plan afﬁliated with i3 Innovus were analyzed
with a retrospective cohort design. Adults newly diagnosed with
major depressive disorder (n = 4447) from July 2000 to Decem-
ber 2002 who started a course of antidepressant treatment were
included. Follow-up visits during the ﬁrst three months after the
index prescription were counted, and patients were classiﬁed as
receiving guideline-concordant care if they had at least three
visits. Logistic regression was used to explore the predictors for
having the minimum number of recommended follow-up visits.
RESULTS: The mean number of follow-up visits during acute
phase treatment was 2.68. Only 43.4% of patients received
guideline-recommended level of follow-up care. In regression
analysis, an initial prescription from a psychiatrist was the stron-
gest predictor (OR = 2.66, 95% CI = 2.30–3.07). Receiving
psychotherapy, having comorbid anxiety, and having a lower
copayment was also positively associated with the probability of
guideline-recommended follow-up care (P < 0.05). CONCLU-
SION: Routine care for antidepressant management falls short of
guideline recommendations, especially in primary care. Modiﬁ-
able factors such as provider of care and copayments appear to
inﬂuence the likelihood of receiving guideline-concordant care.
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OBJECTIVE: Estimate the impact of adhering to lipid treatment
guidelines [National Cholesterol Education Program’s Third
Report on Detection, Evaluation, and Treatment of High Blood
Cholesterol and Adult Treatment Panel’s (NCEP-ATP III)] on
cardiovascular disease (CVD) events and associated costs in a
managed care population. METHODS: A retrospective analysis
was conducted using the HealthCore Integrated Research
Database on patients with laboratory values on low-density
lipoprotein-cholesterol (LDL-C), high-density lipoprotein-
cholesterol (HDL-C), & triglycerides (TG) between Janaury 1,
2003-December 31, 2005 [index date], no lipid therapy
6-months pre-index date, and minimum 12 months health plan
eligibility pre- and post-index date. Baseline lipid levels and the
ﬁrst post-index follow-up lipid panel (goal attainment), and risk
stratiﬁcation per NCEP-ATP III guidelines were used to catego-
rize patients as appropriately (AM) or inappropriately managed
(IAM). End points included counts of CVD events (ischemic
heart disease, peripheral vascular disease, stroke and related
occurrences and interventions) through Poisson regression and
associated annual total CVD-attributable costs ($CV) during
follow-up (multivariate generalized linear model regression)
between groups after controlling for baseline clinical and demo-
graphic differences. RESULTS: A total of 8176 patients (3493
AM; 4683 IAM) were identiﬁed. AM patients were signiﬁcantly
older [mean (SD) ages of 51.4 (9.1) vs. 50.0 (9.6); p < 0.01] and
comprised of fewer males (43.2% vs. 56.2%; p < 0.01). Baseline
Deyo-Charlson comorbidity scores were signiﬁcantly lower
among AM patients (0.20  0.44 vs. 0.32  0.56; p < 0.01).
During follow-up, AM patients had a 10% reduction in the
annual rate of CV events [Annual Event Rate (AER) = 0.90; 95%
CI, 0.86–0.93] as compared to IAM patients. A 12% reduction
in annual total $CV [Estimate: 0.88 (95% CI, 0.80–0.98) [$696
vs. $788; p = 0.02] was observed among AM patients versus
IAM patients. CONCLUSION: Comprehensive dyslipidemia
management reﬂecting clinical guideline treatment recommenda-
tions was associated with reductions in CVD events and $CV in
this managed care population.
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OBJECTIVE: There is much controversy about the value of new
medications and the substantial spending on R&D associated
with new treatments. The current study aimed at evaluating the
impact of drug innovation on longevity in three important
disease areas using patient-level data. METHODS: An analysis
of health claims from Quebec’s provincial health plan data
A4 Abstracts
